-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Boosting Innovation: Shijiazhuang Sihua Pharmaceutical Equips Its Core Research Personnel with 66 Mobility Devices in the First Batch
Category:
发布时间：2021-09-15
【概要描述】
On September 15, Shijiazhuang Sihua Pharmaceutical Group held a handover ceremony to equip the first batch of 66 mobility aids for its R&D core personnel, assigning these vehicles to project leaders and key research staff.
“The company has provided us R&D personnel with company cars—what an exhilarating feeling!” On September 15, at the ceremony held by Shijiazhuang Sihua Pharmaceutical Group to officially hand over the first batch of 66 company vehicles to its core R&D staff, the atmosphere was electric. Liu Yali, head of clinical projects at the Group’s Research Institute, and her colleagues could hardly contain their joy as they gazed at the neatly lined-up sedans in the plaza in front of the company’s R&D building, their eyes brimming with anticipation and pride.
According to reports, Shijiazhuang Sihua Pharmaceutical Group has allocated the first batch of 66 mobility aids to heads of R&D projects and key research personnel, with more such aids to be provided in subsequent phases to other innovative research talent.
The key to innovation lies in attracting and retaining top talent. Over the past two years, R&D personnel—charged with the critical mission of strengthening the company through technology—have become highly sought-after at Shijiazhuang Sihua Pharmaceutical. The company not only provides a world-class research environment and a pleasant, people-oriented office setting, but also offers industry-leading compensation and has built an “Experts’ Residence” to address the housing needs of its scientific staff. Moreover, the company has thoughtfully addressed the mobility needs of its R&D team by providing each member with a personal vehicle. By creating an environment where talent can work with satisfaction, comfort, and peace of mind, the company has greatly boosted the enthusiasm and motivation of its researchers to dedicate themselves to scientific and technological development.
“As a researcher at Sihua Pharmaceutical, I feel truly fortunate!” Liu Yali said excitedly upon receiving the keys to her new car. “To enable us to focus wholeheartedly on scientific research and innovation, the company has not only improved our working environment and enhanced our compensation and benefits, but also introduced preferential housing policies and provided company-provided transportation for work. I will cherish this platform and these excellent conditions that the company has created for us more than ever, remain committed to the front lines of innovation, weather challenges and hone my skills, strengthen my resolve, and, through hard work and ingenuity, deliver research outcomes that do justice to both the company and our times.”
“Our incentives for research personnel are unprecedented!” Qu Jiguang, Chairman of the Board of Shijiazhuang Sihua Pharmaceutical Group, told reporters. “Innovation-driven development is, at its core, talent-driven. Only by implementing a talent-first development strategy can we transform our human-resource advantages into competitive strengths for corporate innovation and growth. All that our company is doing is aimed at fostering a robust ecosystem for talent-driven innovation—at attracting and harnessing top talent from across the globe, providing broader space and a more expansive platform for all kinds of innovative professionals to showcase their abilities, and enabling R&D personnel to devote themselves wholeheartedly to scientific research and innovation without distraction, thereby contributing to the company’s high-quality development.”
These incentive measures have effectively propelled the high-quality development of corporate R&D and innovation. In recent years, Shijiazhuang Sihua Pharmaceutical has successively been approved to establish high-end R&D and innovation platforms such as the National Enterprise Technology Center and the National–Local Joint Engineering Laboratory. The company has also jointly set up close-knit pharmaceutical joint research and innovation centers with leading universities including China Pharmaceutical University, Tianjin University, Zhejiang University, and Hebei University, focusing on diversified innovation across therapeutic areas such as oncology, respiratory diseases, digestive and metabolic disorders, neurological conditions, cardiovascular diseases, and anti-infectives. This has fostered a synergistic innovation ecosystem encompassing generic drugs, innovative medicines, active pharmaceutical ingredients, and pharmaceutical packaging materials, putting the company’s scientific research and innovation on a “highway” of greater standardization, institutionalization, and systematization. As a result, Shijiazhuang Sihua Pharmaceutical has successfully ranked among the Top 30 Chinese enterprises with the best R&D product pipelines and the Top 50 in overall pharmaceutical R&D strength, continuously elevating its position within the top 100 of China’s pharmaceutical industry and earning recognition as a National Demonstration Enterprise for Technological Innovation. Currently, the group has more than 200 new products in development, including five Class I new drugs, over ten domestically first-generic drugs, and no fewer than 50 specialty APIs. A total of 16 drug varieties comprising 21 specifications have either passed or are deemed to have passed the consistency evaluation, while more than 60 new products are currently under review at the national level. Going forward, the company expects to obtain approval for an average of more than two new products each month. These encouraging figures have drawn widespread attention from the industry, as new products continue to inject fresh momentum into Shijiazhuang Sihua Pharmaceutical’s sustained growth.
Today, more than 80% of Shijiazhuang Sihua Pharmaceutical’s profits are generated by new or upgraded products, demonstrating how innovation has powerfully driven the company’s transformative growth. From January to August this year, both sales revenue and profits and taxes posted double-digit growth. “We will seize the rare opportunities presented by provincial and Shijiazhuang municipal support for the development of the biopharmaceutical industry and strive to make a pioneering contribution to breakthroughs in Shijiazhuang’s biopharmaceutical sector,” said Qu Jiguang with full confidence.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091